VLST is developing a platform around the identification and understanding of the function of virulence factors, a set of proteins in viruses that down regulate the host's immune response, thereby conferring a survival advantage. Understanding this evolutionary process can lead to the identification of a group of clinically relevant cellular targets, as the predicate for the development of therapeutics.
201 Elliott Avenue West
Suite 450
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.